[Immediate post TURBT MMC instillation.]

Area of Science:

• Oncology
• Urology
• Pharmacology

Background:

• Mitomycin C (MMC) is an alkylating antibiotic agent that inhibits DNA synthesis.
• It is widely used as intravesical chemotherapy for urothelial carcinoma.
• Its efficacy in single early postoperative instillation was established in 1988 and supported by extensive clinical evidence.

Purpose of the Study:

• To provide a comprehensive, updated review of single early intravesical Mitomycin C instillation post-transurethral resection of bladder tumors (TURBT).
• To examine the available clinical evidence, international guideline recommendations, and potential complications.
• To discuss strategies for optimizing the use of Mitomycin C.

Main Methods:

• Comprehensive literature review of clinical trials and meta-analyses.
• Analysis of international clinical guidelines.
• Evaluation of reported complications and optimization techniques.

Main Results:

• Level 1a evidence supports the use of single early postoperative intravesical Mitomycin C instillation.
• Multiple clinical trials and meta-analyses confirm its efficacy.
• Established guidelines recommend its use in specific contexts.

Conclusions:

• Single early intravesical Mitomycin C instillation is a well-established and evidence-based adjuvant treatment for urothelial carcinoma.
• Understanding its efficacy, complications, and optimization strategies is crucial for clinical practice.
• Continued research may further refine its application and patient outcomes.